{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Han S"],"funding":["NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases"],"pagination":["e00888"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12456583"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(9)"],"pubmed_abstract":["<h4>Introduction</h4>Chronic pancreatitis (CP) remains difficult to manage with few treatment options. Prior studies have implicated prostaglandin E 2 (PGE 2 ) in mediating chronic inflammation in the pancreas. Therefore, we aimed to evaluate whether indomethacin, a cyclooxygenase-2 enzyme inhibitor, would reduce PGE 2 levels in CP.<h4>Methods</h4>In this pilot multicenter randomized controlled trial, participants with CP received oral indomethacin (50 mg) or placebo twice daily for 28 days. Measurement of PGE 2 levels in pancreatic fluid collected endoscopically after secretin administration at baseline and posttreatment (day 28) was performed. Quality of life and pain were also assessed at baseline and posttreatment.<h4>Results</h4>A total of 27 participants were randomized (indomethacin"],"journal":["Clinical and translational gastroenterology"],"pubmed_title":["Oral Indomethacin for Chronic Pancreatitis: Results From the PAIR Randomized Placebo-Controlled Trial."],"pmcid":["PMC12456583"],"funding_grant_id":["R21 DK117212","R21DK117212"],"pubmed_authors":["Saloman JL","Cruz-Monserrate Z","Hill R","Hao W","Yadav D","Han S","Li L","Xu J","Conwell DL","Hart PA","Vege SS","Topazian M","Palermo TM"],"additional_accession":[]},"is_claimable":false,"name":"Oral Indomethacin for Chronic Pancreatitis: Results From the PAIR Randomized Placebo-Controlled Trial.","description":"<h4>Introduction</h4>Chronic pancreatitis (CP) remains difficult to manage with few treatment options. Prior studies have implicated prostaglandin E 2 (PGE 2 ) in mediating chronic inflammation in the pancreas. Therefore, we aimed to evaluate whether indomethacin, a cyclooxygenase-2 enzyme inhibitor, would reduce PGE 2 levels in CP.<h4>Methods</h4>In this pilot multicenter randomized controlled trial, participants with CP received oral indomethacin (50 mg) or placebo twice daily for 28 days. Measurement of PGE 2 levels in pancreatic fluid collected endoscopically after secretin administration at baseline and posttreatment (day 28) was performed. Quality of life and pain were also assessed at baseline and posttreatment.<h4>Results</h4>A total of 27 participants were randomized (indomethacin","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-07-15T14:23:02.553Z","creation":"2026-07-05T03:12:20.212Z"},"accession":"S-EPMC12456583","cross_references":{"pubmed":["40622408"],"doi":["10.14309/ctg.0000000000000888"]}}